- Home
- CRGX vs CTO Comparison
CRGX vs CTO Comparison
Compare CRGX & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- CTO
- Stock Information
- Founded
- CRGX 2021
- CTO 1902
- Country
- CRGX United States
- CTO United States
- Employees
- CRGX N/A
- CTO N/A
- Industry
- CRGX
- CTO Real Estate Investment Trusts
- Sector
- CRGX
- CTO Real Estate
- Exchange
- CRGX Nasdaq
- CTO Nasdaq
- Market Cap
- CRGX 190.0M
- CTO 589.6M
- IPO Year
- CRGX 2023
- CTO N/A
- Fundamental
- Price
- CRGX $4.16
- CTO $17.19
- Analyst Decision
- CRGX Hold
- CTO Strong Buy
- Analyst Count
- CRGX 7
- CTO 3
- Target Price
- CRGX $4.67
- CTO $22.33
- AVG Volume (30 Days)
- CRGX 586.4K
- CTO 348.4K
- Earning Date
- CRGX 08-11-2025
- CTO 07-29-2025
- Dividend Yield
- CRGX N/A
- CTO 8.82%
- EPS Growth
- CRGX N/A
- CTO N/A
- EPS
- CRGX N/A
- CTO N/A
- Revenue
- CRGX N/A
- CTO $132,203,000.00
- Revenue This Year
- CRGX $57.81
- CTO $20.11
- Revenue Next Year
- CRGX N/A
- CTO $8.51
- P/E Ratio
- CRGX N/A
- CTO N/A
- Revenue Growth
- CRGX N/A
- CTO 17.48
- 52 Week Low
- CRGX $3.00
- CTO $16.12
- 52 Week High
- CRGX $25.45
- CTO $21.15
- Technical
- Relative Strength Index (RSI)
- CRGX 45.07
- CTO 36.24
- Support Level
- CRGX $4.33
- CTO $16.84
- Resistance Level
- CRGX $4.36
- CTO $18.39
- Average True Range (ATR)
- CRGX 0.19
- CTO 0.37
- MACD
- CRGX -0.04
- CTO -0.13
- Stochastic Oscillator
- CRGX 21.76
- CTO 21.30
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.